Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380137 | 0.84 | TSHR (0.66) | GAAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL11191041 | 0.83 | ALOX15 (0.56) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL11191103 | 0.81 | ALOX15 (0.54) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL9527006 | 0.81 | ALOX15 (0.54) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL16652519 | 0.81 | ALOX15 (0.50) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL5203267 | 0.80 | ALOX15 (0.53) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL12496081 | 0.80 | ALOX15 (0.53) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL293394 | 0.79 | TSHR (0.57) | GAAPOLBTSHRLMNAALDH1A1 | |
| SCHEMBL8176741 | 0.79 | ALOX15 (0.51) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL3707572 | 0.79 | LMNA (0.73) | ALOX15GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| WO-2016040081-A1 | QUINAZOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | claimed |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-10 | — | — | US | claimed |
| US-9266835-B2 | Quinoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | claimed |
| WO-2015130444-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | WO | claimed |
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | claimed |
| CN-1976916-A | Selected CGRP-antagonists, method for the production thereof and their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2007-06-06 | — | — | CN | claimed |
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-9464055-B2 | Quinoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-11 | — | — | US | disclosed |
| WO-2016040081-A1 | QUINAZOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-9266835-B2 | Quinoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | disclosed |
| WO-2015130444-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130445-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239845-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| CN-1976916-A | Selected CGRP-antagonists, method for the production thereof and their use as medicaments | BOEHRINGER INGELHEIM INT (DE) | 2007-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239844-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | ALOX15 2214/4885GAA 1847/4885MGAM 4250/4885 |
| US-20150239845-A1 | QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, GPR119 | ALOX15 2214/4885GAA 1847/4885MGAM 4250/4885 |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | CNR1, CNR2, GPR119 | ALOX15 2594/4885GAA 1794/4885MGAM 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.